Valuation : Viyash Scientific Limited

Market Cap 112B 1.17B 1.01B 953M 868M 1.62B 1.64B 11.35B 4.37B 56.95B 4.41B 4.31B 181B P/E 2027 *
37.3x
P/E 2028 * 22.5x
Enterprise Value 112B 1.17B 1.01B 953M 868M 1.62B 1.64B 11.35B 4.37B 56.95B 4.41B 4.31B 181B EV / Sales 2027 *
2.88x
EV / Sales 2028 * 2.51x
Free-Float
32.8%
Yield 2027 *
-
Yield 2028 * -
1 day-1.09%
1 week-1.09%
Current month-2.28%
1 month-5.87%
3 months+2.10%
6 months+30.46%
Current year+23.53%
1 week 253.5
Extreme 253.5
266.9
1 month 245.3
Extreme 245.3
280
Current year 178.13
Extreme 178.13
298
1 year 178.13
Extreme 178.13
298
3 years 86.4
Extreme 86.4
298
5 years 61.8
Extreme 61.8
298
10 years 42.65
Extreme 42.65
336.5
Manager TitleAgeSince
Chief Executive Officer 62 16/12/2025
Director of Finance/CFO - 01/01/2026
Chief Tech/Sci/R&D Officer - 05/02/2026
Director TitleAgeSince
Chairman 78 -
Director/Board Member 67 25/08/2020
Director/Board Member 57 11/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-1.09% - - 1.19B
-0.12%-2.52%+48.15%+88.13% 1,001B
+0.21%-2.77%+49.91%+64.51% 642B
+0.58%-0.03%+16.42%+72.02% 451B
-0.39%-3.45%+28.43%+35.76% 340B
-0.04%-13.47%+10.16%+26.96% 263B
-0.20%-2.22%-1.81%+11.79% 247B
-0.72%-13.12%+34.35%+45.14% 207B
-3.44%-7.51%-20.08%-59.58% 197B
-0.71%-4.71%+22.09%+86.77% 180B
Average -0.62%-5.53%+20.85%+41.28% 391.82B
Weighted average by Cap. -0.30%-4.65%+30.24%+55.98%

Financials

2027 *2028 *
Net sales 38.99B 408M 351M 331M 301M 564M 569M 3.94B 1.52B 19.78B 1.53B 1.5B 62.82B 44.68B 467M 402M 379M 345M 646M 652M 4.52B 1.74B 22.66B 1.76B 1.72B 71.99B
Net income 3.44B 35.96M 30.93M 29.18M 26.58M 49.7M 50.15M 348M 134M 1.74B 135M 132M 5.54B 5.4B 56.43M 48.53M 45.79M 41.71M 77.98M 78.69M 545M 210M 2.74B 212M 207M 8.69B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
11/09/26 257.60 -1.09% 1,859,725
10/09/26 ₹260.45 -0.55% 3,107,823
09/09/26 ₹261.90 -0.02% 2,327,034
08/09/26 ₹261.95 -0.64% 2,245,212
07/09/26 ₹263.65 -0.83% 2,271,312
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
260.90INR
Average target price
322.25INR
Spread / Average Target
+23.51%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!